MRNA

Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

Moderna NASDAQ: MRNA executives emphasized the company's evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development.

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at scale. Moderna stock is at $181.

Moderna's 52-week high follows positive melanoma results, with detailed phase III data set for an ESMO presentation.

One reason that analysts and doctors want to see the data is to better understand how well the personalized treatment works.

Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares are surging Monday morning after the company announced that its Phase 3 adjuvant melanoma study for intismeran autogene, an investigational messenger RNA individualized neoantigen therapy, was selected for a Presidential Symposium slot at

As the bulls reassert their power, leading stocks like SanDisk, Coinbase, and Moderna are setting up in constructive base structures.

Moderna (MRNA) stock continued to rise on Thursday as investors assessed positive late-stage results for the company's personalised mRNA cancer vaccine and a series of analyst upgrades and higher price targets. The main catalyst has been the Phase 3 success of intismeran autogene, Moderna's personalised mRNA cancer vaccine being developed with Merck's Keytruda.

Cancer vaccine momentum is doing the work for Moderna (NASDAQ:MRNA | MRNA Price Prediction) once again on Thursday, extending one of the sharpest one-month runs in large-cap biotech this year without a fresh disclosure attached to it.